Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Novavax strikes deal with Pfizer for immune-boosting tech worth up to $530M

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...
Pharmaceutical Technology

JPM26: Matrix-M Technology is central to Novavax’s strategy

Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...
Hosted on MSN

Novavax Enters Lease Agreement with AstraZeneca

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from ...
Morningstar

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

GAITHERSBURG, Md., Nov. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling ...
Hosted on MSN

FDA approves Novavax COVID-19 shot but with unusual restrictions

WASHINGTON (AP) — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional ...
Seeking Alpha

Novavax rises after a seven-day slide

Novavax (NVAX) rose 3.70% to close at $6.45 on Friday, snapping a seven-session losing streak, with notable drops of 3.38% and 3.50% on November 18 and 19. Novavax now expects to reach profitability ...